



CONTENTS

Corporate Information	2
Chairman's Statement	4
Chief Executive Officer's Review	5
Operation Highlights	7
Management Discussion and Analysis	14
Report of the Board of Directors	40
Report of the Board of Supervisors	63
Corporate Governance Report	64
Biographical Details of Directors, Supervisors and Senior Management	86
Independent Auditor's Report	94
Consolidated Statement of Profit or Loss	99
Consolidated Statement of Comprehensive Income	100
Consolidated Statement of Financial Position	101
Consolidated Statement of Changes in Equity	102
Consolidated Statement of Cash Flows	103
Notes to Financial Statements	105
Definitions	179



CORPORATE GOVERNANCE REPORT

lated depreciatio	–	(368,914)	(622)	(
			54,490	177,3
	560,106	332	116,786 92	346,7
	929,020	954	625	

shares
a eligible participant at an exercise pri
2022 Share Award Scheme*On 48 February 2022, pu*

R

(

and inventory of RMB2,000 for the year ended 321December 4023 in respect

The Group has5recognised expenses of RMB2,286,000, deferred development costs of RMB38,000, cost of

share), and the fair value is determined by the stock price on the date of grant of the Share Award Scheme.

The aggregate fair value of the shares granted amounted to approximately RMB396,000 (42,000 shares with RMB9.44 per

ed 31 December 2023

[illegible] cts. [illegible] ese a[illegible] unts a[illegible] t[illegible] in natu[illegible], unsecu[illegible] an[illegible] th inte[illegible] st [illegible] cognise[illegible] hich [illegible] sente[illegible] the signi[illegible] cant [illegible] nancing

20232022

In this annual report, the following expressions have the meanings set out below unless the context requires otherwise.

"2018 Share Award Scheme"	the share award scheme adopted pursuant to the original operating procedure of the employee equity incentive scheme signed in April 2018
"2020 Share Award Scheme"	the share award scheme proposed to be adopted pursuant to the operating procedure of the 2020 employee equity incentive scheme
"A Share(s)"	RMB ordinary share(s) proposed to be issued by the Company pursuant to the A Share Offering
"A Share Offering"	the Company's proposed initial public offering of A Shares, which are proposed to be listed on the Science and Technology Innovation Board of Shanghai Stock Exchange
"A Share Offering and Listing"	the Company's proposed initial public offering of A Shares, and the listing of such Shares on the Science and Technology Innovation Board of Shanghai Stock Exchange
"Accord"	Accord Healthcare Limited
"AMTD"or "Investment Manager"	AMTD Global Markets Limited (now renamed as orientiert XYZ Securities Limited)

"

DEFINITIONS

"Hong Kong Stock Exchange" or the "Stock Exchange"	The Stock Exchange of Hong Kong Limited
"IFRSs"	International Financial Reporting Standards
"IMA"	the investment management agreement dated on 25 September 2019 entered into between the Company and AMTD
"IND"	investigational new drug or investigational new drug application, also known as clinical trial application in China
"Intas"	Intas Pharmaceuticals Limited, founded in 1976 and headquartered in India
"Jiangsu Fosun"	Jiangsu Fosun Pharmaceutical Sales Co., Ltd., a company incorporated in the PRC with limited liability, and a wholly owned subsidiary of Fosun Pharma
"Jiangsu Wanbang"	Jiangsu Wanbang (Group) Biopharmaceutical Co., Ltd., a company incorporated in the PRC with limited liability, and a wholly owned subsidiary of Fosun Pharma
"Latest Practicable Date"	10 April 2024, being the latest practicable date for ascertaining the contents set out in this report prior to printing
"Listing"	the listing of the H Shares on the Main Board of the Stock Exchange
"Listing Date"	25 September 2019, being the date on which the H Shares were listed on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
"MAA"	marketing authorisation application
"mAb"	monoclonal antibodies
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules
"NDA"	new drug application
"NMPA"	the National Medical Products Administration of the PRC
"PRC", "China" or "Mainland China"	the People's Republic of China, but for the purposes of this annual report only, except where the context requires, references in this annual report to PRC, China or Mainland China exclude Hong Kong, Macau and Taiwan Regions
"Promotional Services Agreement"	the agreement entered into by Henlius Biopharmaceuticals and Jiangsu Fosun on 24 August 2020 in relation to the provision of promotional services by Jiangsu Fosun to the Group, as amended by a supplemental agreement on 31 December 2020, 30 June 2022 and 29 December 2023